“The exemption expires 27 November 2026” is true and almost useless on its own. It does not tell you what lands on you that day, and it does not distinguish between the parts your wholesaler already handles and the parts nobody is handling.
The exemption is written against a specific list: the requirements of §582(g)(1) of the Federal Food, Drug and Cosmetic Act, lettered (A) through (F). The FDA sets them out one by one in the same document that grants the relief. Read as six obligations rather than one deadline, the shape of the work changes.
The six, in the FDA’s own terms
Quoted from the exemptions document, condensed only where the statutory cross-references run long:
- (A) Electronic, interoperable exchange.That transaction information and transaction statements “be exchanged in a secure, interoperable, electronic manner” under the standards in the §582(h) guidances. This is the EPCIS-shaped part.
- (B) Package-level product identifier.That the transaction information “include the product identifier (e.g., the National Drug Code, serial number, lot number, and expiration date) at the package level for each package included in the transaction.”
- (C) Package-level verification. Systems and processes for verification of product at the package level, including the standardized numerical identifier, in accordance with the §582 guidances.
- (D) Prompt response to an official request.Systems and processes “necessary to promptly respond with the transaction information and transaction statement for a product upon a request by the Secretary, or other appropriate Federal or State official, in the event of a recall or for the purposes of investigating a suspect product or an illegitimate product.”
- (E) Gathering information back to the manufacturer. Systems and processes to promptly facilitate gathering the transaction information for each transaction going back to the manufacturer — on an official request, or on a request from an authorised trading partner made securely.
- (F) Saleable returns.That anyone accepting a saleable return have systems and processes in place to accept it, and accept it “only if such person can associate the saleable return product with the transaction information and transaction statement for the product.”
Which of these is actually your problem
(A), (B) and (C) are data obligations that move with the product. For an independent pharmacy buying from a primary wholesaler, the serialized data is generated upstream and delivered into a portal or a feed you already have. The work there is confirming the connection exists and that someone knows where the data lands — not building a tracing platform.
(D) and (E) are the ones that catch people, because they are not about data at all. They are about systems and processes — whether a request arriving on a Tuesday reaches a named person, who pulls what, and how fast. A pharmacy can hold every byte of required data and still fail (D) because no one has ever written down who answers.
(F) is narrow and often mis-scoped. It bites on returns you accept back into saleable inventory, which for most independents is a thin flow — but the obligation is to be able to associate the return with its transaction information, which is a procedure, not a purchase.
Two things people get wrong about the date
If you have 26 or more full-time pharmacists and technicians, this is not your date. The relief FDA granted to larger dispensers ran “from November 27, 2024, until November 27, 2025.” That window closed eight months ago. There is no automatic grant carrying a 26+ FTE dispenser to 2026, and individually granted waivers carry their own end dates. Count across the whole corporate entity before assuming which of the two dates applies to you — this is the single most common misreading, and we have written it up in full.
Do not rebuild transaction history.The FDA notes in the same document that “Beginning on November 27, 2023, section 582(k)(1) of the FD&C Act effectively ended the requirement for trading partners to provide and receive transaction history.” It is worth saying because older compliance checklists still list three documents — TI, TH and TS. Preparing for the sunset by reconstructing a requirement that was retired is wasted work.
What to have ready before the date
None of (D), (E) or (F) is satisfied by an intention. Each is satisfied by a dated, findable written procedure that an inspector can read and a member of staff can follow. Concretely:
- A dated determination of which exemption track you are on, with the entity-wide count behind it.
- A trading-partner verification log — who you buy from, and how you established they are authorised.
- A tracing response runbook naming the person, the source system and the turnaround.
- Suspect and illegitimate product SOPs, including quarantine and FDA notification.
- A saleable-returns procedure that ties a return to its transaction information.
- Training attestation and a retention plan covering the six-year requirement.
Where DoseTrace fits
DoseTrace does not move serialized data and is not an EPCIS platform — (A), (B) and (C) stay with your wholesaler and your existing systems. It produces the nine-document binder that covers the written half, from a 15-minute intake, flat fee $499, one time, no subscription.
Check which exemption track you are on, free — it takes about a minute and stores nothing. Contact reaches a person.
If you are being sold a platform for (A), (B) and (C) and are not sure whether it also covers (D), (E) and (F), that boundary is the whole of DSCSA software or a readiness binder.
Every quotation on this page is from the FDA document DSCSA Exemptions from Section 582(g)(1) and Other Requirements of the FD&C Act for Certain Trading Partners, issued 9 October 2024, retrieved and verified 28 July 2026. DoseTrace is not a law firm and nothing here is legal advice.